title: A prospective evaluation of treatment with Selective Internal Radiation Therapy (SIR-spheres) in patients with unresectable liver metastases from colorectal cancer previously treated with 5-FU based chemotherapy.
abstract: BACKGROUND
  To prospectively evaluate the efficacy and safety of Selective Internal Radiation (SIR) spheres in patients with inoperable liver metastases from colorectal cancer who have failed 5FU based chemotherapy.
  
  
  METHODS
  Patients were prospectively enrolled at three Australian centres. All patients had previously received 5-FU based chemotherapy for metastatic colorectal cancer. Patients were ECOG 0-2 and had liver dominant or liver only disease. Concurrent 5-FU was given at investigator discretion.
  
  
  RESULTS
  Thirty patients were treated between January 2002 and March 2004. As of July 2004 the median follow-up is 18.3 months. Median patient age was 61.7 years (range 36-77). Twenty-nine patients are evaluable for toxicity and response. There were 10 partial responses (33%), with the median duration of response being 8.3 months (range 2-18) and median time to progression of 5.3 mths. Response rates were lower (21%) and progression free survival shorter (3.9 mths) in patients that had received all standard chemotherapy options (n = 14). No responses were seen in patients with a poor performance status (n = 3) or extrahepatic disease (n = 6). Overall treatment related toxicity was acceptable, however significant late toxicity included 4 cases of gastric ulceration.
  
  
  CONCLUSIONS
  In patients with metastatic colorectal cancer that have previously received treatment with 5-FU based chemotherapy, treatment with SIR-spheres has demonstrated encouraging activity. Further studies are required to better define the subsets of patients most likely to respond.
authors.affiliation: The Royal Melbourne Hospital, Parkville, Victoria, Australia. lionellim@optusnet.com.au
authors.forename: L
authors.initials: L
authors.lastname: Lim
authors.forename: P
authors.initials: P
authors.lastname: Gibbs
authors.forename: D
authors.initials: D
authors.lastname: Yip
authors.forename: J D
authors.initials: JD
authors.lastname: Shapiro
authors.forename: R
authors.initials: R
authors.lastname: Dowling
authors.forename: D
authors.initials: D
authors.lastname: Smith
authors.forename: A
authors.initials: A
authors.lastname: Little
authors.forename: W
authors.initials: W
authors.lastname: Bailey
authors.forename: M
authors.initials: M
authors.lastname: Liechtenstein
mesh_terms: D000328:Adult; D000368:Aged; D000964:Antimetabolites, Antineoplastic / Q000627:therapeutic use; D001706:Biopsy; D015179:Colorectal Neoplasms / Q000188:drug therapy* / Q000473:pathology* / Q000532:radiotherapy*; D018572:Disease-Free Survival; D019008:Drug Resistance, Neoplasm; D005260:Female; D005472:Fluorouracil / Q000627:therapeutic use*; D005753:Gastric Mucosa / Q000473:pathology; D006801:Humans; D007249:Inflammation; D008113:Liver Neoplasms / Q000532:radiotherapy* / Q000556:secondary*; D008297:Male; D008863:Microspheres; D008875:Middle Aged; D009362:Neoplasm Metastasis; D011446:Prospective Studies; D011878:Radiotherapy / Q000379:methods*; D011879:Radiotherapy Dosage; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D000964:Antimetabolites, Antineoplastic; D005472:Fluorouracil